AXL and esophageal cancer: In other cancer types, AXL has been implicated in resistance to doxorubicin and cytosine arabinoside in AML [57], to cisplatin resistance in esophageal cancer [93], to multiple chemotherapies in NSCLC [94], and to 5-FU treatment in colorectal cancer [95].